ReviewHeart failure reviews2016
The evolving role of adiponectin as an additive biomarker in HFrEF.
Review in Heart failure reviews, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.
- Association between elevated adiponectin level and adverse outcomes in patients with heart failure: a systematic review and meta-analysis.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2019Pooled it
- The Role of Serum Adiponectin for Outcome Prediction in Patients with Dilated Cardiomyopathy and Advanced Heart Failure.BioMed research international · 2017Trial
- Adiponectin and metabolic cardiovascular diseases: Therapeutic opportunities and challenges.Genes & diseases · 2023Review
- Adiponectin: friend or foe in obesity and inflammation.Medical review (2021) · 2022Review
- Association between Serum Adiponectin and Atrial Fibrillation: A Case-Control Study Stratified by Age and Gender.Cardiology research and practice · 2021Article
- The Role of Cardiac T-Cadherin in the Indicating Heart Failure Severity of Patients with Non-Ischemic Dilated Cardiomyopathy.Medicina (Kaunas, Lithuania) · 2020Article
- Adiponectin: a therapeutic target in the antiphospholipid syndrome?Rheumatology international · 2019Review
- Myocardial Adiponectin Isoform Shift in Dogs with Congestive Heart Failure-A Comparison to Hibernating Brown Bears (Ursus arctos horribilis).Veterinary sciences · 2017Article
- Cardiovascular Adiponectin Resistance: The Critical Role of Adiponectin Receptor Modification.Trends in endocrinology and metabolism: TEM · 2017Review
- Identification of Highly Specific scFvs against Total Adiponectin for Diagnostic Purposes.Biology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure (HF) is a growing health problem. Despite improved management and outcome, the number of patients with HF is expected to keep rising in the following years. In recent research, adiponectin was shown to exert beneficial effects in the cardiovascular system, but the protein was also implicated in the development and progression of HF. The objective of this review is to provide an overview of current knowledge on the role of adiponectin in HF with reduced ejection fraction. We discuss the cardioprotective and (anti-) inflammatory actions of adiponectin and its potential use in clinical diagnosis and prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.